Jatrorrhizine

Jatrorrhizine is a protoberberine alkaloid (molecular formula C₂₀H₂₀NO₄) that exerts antibacterial, antifungal, anti-parasitic, and acetylcholinesterase-inhibitory effects by targeting microbial cell walls, neuraminidase enzymes, and cholinergic pathways. Preclinical data demonstrate MIC values of 16–64 μg/mL against Candida auris and an AChE inhibitory IC₅₀ of 0.57 μM, though no human clinical trials have yet confirmed therapeutic efficacy or safe dosing in people.

Origin & History

Jatrorrhizine is a protoberberine isoquinoline alkaloid naturally occurring in several medicinal plants central to traditional Chinese medicine, including Coptis chinensis (goldthread), Berberis vernae, Tinospora sagittata, and Phellodendron chinense, which grow predominantly across temperate and subtropical regions of China, Tibet, and Southeast Asia. These source plants are cultivated in moist, shaded mountain environments, particularly in Sichuan, Yunnan, and Guizhou provinces of China, where Coptis chinensis has been harvested for over 2,000 years. Jatrorrhizine can also be produced synthetically via the Pictet-Spengler reaction starting from phenethylamine, achieving approximately 20% overall yield, enabling research-grade supply independent of botanical harvesting.

Historical & Cultural Context

Jatrorrhizine-containing plants, particularly Coptis chinensis (known as Huang Lian in Chinese), have been documented in Chinese materia medica for over 2,000 years, with references appearing in classical texts such as the Shennong Bencao Jing (Divine Farmer's Classic of Materia Medica, circa 200 CE) for the treatment of gastrointestinal infections, 'heat toxins,' gastritis, and stomachache. In traditional Chinese medicine theory, Huang Lian is classified as bitter and cold in nature, attributed to the Heart, Stomach, and Large Intestine meridians, and prescribed to clear heat, dry dampness, and resolve toxicity—functions now partially explained by the antimicrobial and anti-inflammatory properties of its constituent alkaloids including jatrorrhizine, berberine, and coptisine. Phellodendron chinense (Huang Bai) and Berberis species similarly occupy important roles in Ayurvedic and Tibetan medical traditions, where bark preparations were used as topical antiseptics and digestive bitters. The isolation and structural characterization of jatrorrhizine as a distinct alkaloid entity from these botanical sources in the modern pharmacognosy era has enabled targeted mechanistic research separating its contributions from the broader alkaloid matrix.

Health Benefits

- **Antibacterial and Antifungal Activity**: Jatrorrhizine inhibits Candida auris at MIC values of 16–64 μg/mL by inducing cell wall remodeling, and shows activity against Staphylococcus aureus (MIC 200 μg/mL) and Propionibacterium acnes (MIC 25–50 μg/mL), suggesting utility in combating resistant fungal and bacterial pathogens.
- **Acetylcholinesterase Inhibition (Neuroprotective Potential)**: The compound inhibits acetylcholinesterase with IC₅₀ values reported as low as 0.57 μM, and a synthetic 3-NH₂ derivative shows enhanced potency at IC₅₀ = 0.301 μM, supporting investigational interest in Alzheimer's disease and cholinergic deficit states.
- **Anti-Diabetic and Metabolic Effects**: Animal studies in db/db mice demonstrate that jatrorrhizine modulates gut microbiota composition and reduces blood glucose levels, pointing toward mechanisms relevant to type 2 diabetes management, though human data remain absent.
- **Anti-Parasitic Activity**: Jatrorrhizine exhibits activity against Trypanosoma brucei rhodesiense (IC₅₀ = 4.2 ± 0.002 μg/mL) and Leishmania donovani (IC₅₀ = 20.4 ± 0.03 μg/mL) in vitro, positioning it as a candidate for neglected tropical disease research.
- **Antiviral Neuraminidase Inhibition**: The compound inhibits bacterial neuraminidase at IC₅₀ = 37.0 ± 1.8 μM and viral neuraminidase from rvH1N1 (IC₅₀ = 66.2 ± 4.2 μM) and H5N1 (IC₅₀ = 76.3 ± 2.1 μM) strains in vitro, indicating a potential adjunct role in influenza management.
- **Hypolipidemic and Anti-Obesity Properties**: Preclinical reviews document lipid-lowering and anti-obesity effects associated with jatrorrhizine, plausibly linked to gut microbiome modulation and metabolic enzyme interactions, though quantitative in vivo data are not yet fully characterized.
- **Antioxidant and CNS Modulation**: Jatrorrhizine has demonstrated antioxidant activity and central nervous system effects in preclinical models, potentially through modulation of oxidative stress pathways and cholinergic neurotransmission, supporting broader neuroprotective research interest.

How It Works

Jatrorrhizine exerts its pharmacological effects through multiple molecular mechanisms rooted in its positively charged quaternary nitrogen protoberberine scaffold, which facilitates intercalation into microbial DNA and binding to enzyme active sites. It competitively inhibits acetylcholinesterase (AChE), preventing the hydrolysis of acetylcholine and thereby prolonging cholinergic neurotransmission, with IC₅₀ values as low as 0.57 μM in cell-free assays. Against fungal pathogens such as Candida auris, it triggers cell wall remodeling, likely by disrupting ergosterol biosynthesis or cell wall integrity signaling, while its neuraminidase inhibition (IC₅₀ = 37.0 ± 1.8 μM for bacterial NA) disrupts sialic acid cleavage critical for microbial and viral host-cell adhesion. Metabolic effects in animal models are attributed at least partly to gut microbiota modulation—altering the abundance of specific bacterial taxa—which secondarily impacts glucose homeostasis and lipid metabolism, though precise receptor-level or gene-expression targets such as NF-κB or PI3K/Akt engagement require further mechanistic delineation.

Scientific Research

The evidence base for jatrorrhizine consists entirely of in vitro biochemical assays and preclinical animal studies, with over 400 publications identified in comprehensive reviews but no published human clinical trials as of the current literature search. In vitro studies have quantified AChE inhibition, MIC values against a range of bacterial and fungal pathogens, neuraminidase inhibitory constants, and antiprotozoal IC₅₀ values with reasonable methodological consistency across independent laboratories. Animal model data, notably from db/db diabetic mice, support glucose-lowering and gut microbiome-modulating effects, but species-specific pharmacokinetics limit direct translation to human dosing. The overall evidentiary quality is preclinical; while the volume of studies is substantial, the absence of Phase I/II trials, defined bioavailability data in humans, and randomized controlled trial outcomes means therapeutic conclusions cannot yet be drawn with clinical confidence.

Clinical Summary

No human clinical trials have been conducted specifically isolating jatrorrhizine as an intervention, and therefore no clinical effect sizes, sample sizes, or confidence intervals from randomized controlled trials are available. The compound is consumed indirectly in traditional Chinese medicine formulations such as Coptidis Rhizoma decoctions, but these preparations contain multiple protoberberine alkaloids (berberine, coptisine, palmatine) whose individual contributions are not disambiguated in clinical herbal medicine research. Pharmacological reviews consolidate preclinical data suggesting metabolic, antimicrobial, neuroprotective, and antiparasitic promise, yet the transition from bench findings to validated clinical outcomes remains incomplete. Researchers and clinicians should regard current evidence as hypothesis-generating rather than practice-defining, pending appropriately powered human studies.

Nutritional Profile

Jatrorrhizine is a pure alkaloid compound rather than a nutritional ingredient and does not contribute macronutrients, vitamins, or minerals. As an isolated molecule (MW ≈ 337.37 g/mol as free base; quaternary ammonium salt form commonly used in research), its 'profile' is defined by its phytochemical class: a protoberberine isoquinoline alkaloid with a 2,9,10-trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-3-ol structure conferring the characteristic planar aromatic ring system responsible for DNA/enzyme intercalation. In source plants such as Coptis chinensis, the rhizome additionally contains berberine (the most abundant protoberberine), coptisine, palmatine, columbamine, and epiberberine alongside polysaccharides, ferulic acid derivatives, and trace minerals, but the specific concentration of jatrorrhizine relative to total alkaloid content is not consistently quantified across botanical sources. Bioavailability of protoberberine alkaloids as a class is generally low via oral routes due to limited intestinal absorption and significant first-pass metabolism, a challenge that applies to jatrorrhizine specifically, though human pharmacokinetic data for this compound are lacking.

Preparation & Dosage

- **Traditional Herbal Decoction (TCM)**: Coptidis Rhizoma (Huang Lian), a primary source of jatrorrhizine, is traditionally prepared as an aqueous decoction using 1.5–9 g of dried rhizome per dose; jatrorrhizine contributes alongside berberine and other alkaloids in this multi-compound extract.
- **Standardized Botanical Extracts**: Commercial Coptis chinensis or Phellodendron chinense extracts are sometimes standardized to total protoberberine alkaloid content (commonly 5–10%), but no standardization specifically to jatrorrhizine percentage has been established for supplements.
- **Isolated Compound (Research Grade)**: Pure jatrorrhizine is available as a research chemical (typically >98% HPLC purity) synthesized via Pictet-Spengler routes; no clinically validated supplement dose has been established for the isolated compound.
- **Effective Dose Range**: No human effective dose range has been determined; all pharmacologically active concentrations are derived from in vitro (μM to μg/mL range) and animal studies, which cannot be directly converted to human supplemental doses without pharmacokinetic bridging studies.
- **Timing and Administration Notes**: Traditional TCM preparations are taken orally, typically divided across 2–3 daily doses; absorption, distribution, and first-pass metabolism of jatrorrhizine specifically have not been characterized in human pharmacokinetic studies.

Synergy & Pairings

Within TCM formulations, jatrorrhizine co-occurs with berberine, coptisine, and palmatine in Coptis chinensis preparations; berberine and jatrorrhizine together may exhibit additive or synergistic antimicrobial activity given their shared protoberberine scaffold and overlapping but distinct target affinities, though formal combination index studies are limited. In the context of AChE inhibition, pairing jatrorrhizine or its derivatives with complementary cholinesterase inhibitors or neuroprotective agents such as huperzine A (a Lycopodium alkaloid also used in TCM) represents a theoretically rational stack for cholinergic support, warranting combinatorial preclinical investigation. For metabolic applications, the gut microbiota-modulating effects of jatrorrhizine may synergize with probiotic supplementation or dietary fiber to amplify glycemic benefits, analogous to mechanisms explored for berberine-probiotic combinations in animal models.

Safety & Interactions

The safety profile of isolated jatrorrhizine in humans has not been formally established; no Phase I dose-escalation trials, no established tolerable upper intake levels, and no systematic adverse event documentation exist for the purified compound. Within traditional TCM preparations, Coptis chinensis-derived products containing jatrorrhizine alongside berberine are generally used at modest doses (1.5–9 g herb/day) under practitioner guidance, with potential adverse effects including gastrointestinal discomfort, nausea, and diarrhea consistent with bitter alkaloid ingestion—effects extrapolated from berberine-containing formulas rather than jatrorrhizine-specific data. Drug interaction risk is theoretically significant given structural similarity to berberine, which is known to inhibit CYP3A4 and P-glycoprotein and to potentiate hypoglycemic agents, anticoagulants (e.g., warfarin), and certain antibiotics; these interactions have not been studied for jatrorrhizine independently. Pregnancy and lactation safety is unknown; given the absence of human safety data and the pharmacological activity of protoberberine alkaloids as a class (some of which have demonstrated uterotonic effects in preclinical models), use during pregnancy or lactation should be avoided until evidence is available.